Literature DB >> 22095935

Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.

Roeland Huijgen1, Barbara Sjouke, Kelly Vis, Janine S E de Randamie, Joep C Defesche, John J P Kastelein, G Kees Hovingh, Sigrid W Fouchier.   

Abstract

Autosomal Dominant Hypercholesterolemia (ADH) is caused by LDLR and APOB mutations. However, genetically diagnosed ADH patients do not always exhibit the expected hypercholesterolemic phenotype. Of 4,669 genetically diagnosed ADH patients, identified through the national identification screening program for ADH, 75 patients (1.6%) had LDL-cholesterol (LDL-C) levels below the 50th percentile for age and gender prior to lipid-lowering therapy. The genes encoding APOB, PCSK9, and ANGPTL3 were sequenced in these subjects to address whether monogenic dominant loss-of-function mutations underlie this paradoxical phenotype. APOB mutations, resulting in truncated APOB, were found in five (6.7%) probands, reducing LDL-C by 56%. Rare variants in PCSK9, and ANGPTL3 completely correcting the hypercholesterolemic phenotype were not found. The common variants p.N902N, c.3842+82T>A, p.D2312D, and p.E4181K in APOB, and c.1863+94A>G in PCSK9 were significantly more prevalent in our cohort compared to the general European population. Interestingly, 40% of our probands carried at least one minor allele for all four common APOB variants compared to 1.5% in the general European population. While we found a low prevalence of rare variants in our cohort, our data suggest that regions in proximity of the analyzed loci, and linked to specific common haplotypes, might harbor additional variants that correct an ADH phenotype.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095935     DOI: 10.1002/humu.21660

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  The Lebanese allele at the LDLR in normocholesterolemic people merits reconsideration of genotype phenotype correlations in familial hypercholesterolemia.

Authors:  Akl C Fahed; Fadi F Bitar; Ruby I Khalaf; Elie M Moubarak; Sami T Azar; Georges M Nemer
Journal:  Endocrine       Date:  2012-04-10       Impact factor: 3.633

2.  Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.

Authors:  R Huijgen; S W Fouchier; M Denoun; B A Hutten; M N Vissers; G Lambert; J J P Kastelein
Journal:  J Lipid Res       Date:  2012-02-27       Impact factor: 5.922

3.  Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?

Authors:  Youmna Ghaleb; Sandy Elbitar; Petra El Khoury; Eric Bruckert; Valérie Carreau; Alain Carrié; Philippe Moulin; Mathilde Di-Filippo; Sybil Charriere; Harout Iliozer; Michel Farnier; Gérald Luc; Jean-Pierre Rabès; Catherine Boileau; Marianne Abifadel; Mathilde Varret
Journal:  Eur J Hum Genet       Date:  2018-01-26       Impact factor: 4.246

4.  In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family.

Authors:  Michael Winther; Shoshi Shpitzen; Or Yaacov; Jakob Landau; Limor Oren; Linda Foroozan-Rosenberg; Naama Lev Cohain; Daniel Schurr; Vardiela Meiner; Auryan Szalat; Shai Carmi; Michael R Hayden; Eran Leitersdorf; Ronen Durst
Journal:  J Lipid Res       Date:  2019-08-06       Impact factor: 5.922

5.  Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India.

Authors:  Lakshmi Lavanya Reddy; Swarup A V Shah; Chandrashekhar K Ponde; Jamshed J Dalal; Raj G Jatale; Reeta J Dalal; Rajesh M Rajani; Sudhir K Pillai; Chander V Vanjani; Tester F Ashavaid
Journal:  J Hum Genet       Date:  2021-04-16       Impact factor: 3.172

Review 6.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Authors:  Albert Wiegman; Samuel S Gidding; Gerald F Watts; M John Chapman; Henry N Ginsberg; Marina Cuchel; Leiv Ose; Maurizio Averna; Catherine Boileau; Jan Borén; Eric Bruckert; Alberico L Catapano; Joep C Defesche; Olivier S Descamps; Robert A Hegele; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Jan Albert Kuivenhoven; Luis Masana; Børge G Nordestgaard; Päivi Pajukanta; Klaus G Parhofer; Frederick J Raal; Kausik K Ray; Raul D Santos; Anton F H Stalenhoef; Elisabeth Steinhagen-Thiessen; Erik S Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen; Olov Wiklund
Journal:  Eur Heart J       Date:  2015-05-25       Impact factor: 29.983

7.  Variable expressivity and co-occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy.

Authors:  Akl C Fahed; Ruby Khalaf; Rony Salloum; Rabih R Andary; Raya Safa; Inaam El-Rassy; Elie Moubarak; Sami T Azar; Fadi F Bitar; Georges Nemer
Journal:  Mol Genet Genomic Med       Date:  2016-02-24       Impact factor: 2.183

8.  Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.

Authors:  Chan Joo Lee; Yunbeom Lee; Sungha Park; Seok-Min Kang; Yangsoo Jang; Ji Hyun Lee; Sang-Hak Lee
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

9.  Plasma and adipose tissue level of angiopoietin-like 7 (ANGPTL7) are increased in obesity and reduced after physical exercise.

Authors:  Mohamed Abu-Farha; Preethi Cherian; Irina Al-Khairi; Dhanya Madhu; Ali Tiss; Samia Warsam; Asma Alhubail; Devarajan Sriraman; Faisal Al-Refaei; Jehad Abubaker
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

Review 10.  Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.

Authors:  Nicola Ferri
Journal:  Scientifica (Cairo)       Date:  2012-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.